Education
About Us
Working with TipRanks
Follow Us
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
Total Valuation
VYNE Therapeutics has a market cap or net worth of $8.34M. The enterprise value is $30.93M.
Market Cap$8.34M
Enterprise Value$30.93M
Share Statistics
VYNE Therapeutics has 25,472,164 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding25,472,164
Owned by Insiders4.76%
Owned by Institutions7.24%
Financial Efficiency
VYNE Therapeutics’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -83.63%.
Return on Equity (ROE)-0.76
Return on Assets (ROA)-0.60
Return on Invested Capital (ROIC)-83.63%
Return on Capital Employed (ROCE)-0.84
Revenue Per Employee38.54K
Profits Per Employee-3.06M
Employee Count13
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of VYNE Therapeutics is ―. VYNE Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio284.78
PB Ratio2.74
Price to Fair Value2.74
Price to FCF-4.19
Price to Operating Cash Flow-0.41
PEG Ratio0.05
Income Statement
In the last 12 months, VYNE Therapeutics had revenue of 501.00K and earned -39.83M in profits. Earnings per share was -0.93.
Revenue501.00K
Gross Profit501.00K
Operating Income-43.64M
Pretax Income-39.80M
Net Income-39.83M
EBITDA-43.63M
Earnings Per Share (EPS)-0.93
Cash Flow
In the last 12 months, operating cash flow was -38.36M and capital expenditures -117.00K, giving a free cash flow of -38.48M billion.
Operating Cash Flow-38.36M
Free Cash Flow-38.48M
Free Cash Flow per Share-1.51
Dividends & Yields
VYNE Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.13
52-Week Price Change-86.81%
50-Day Moving Average0.36
200-Day Moving Average1.03
Relative Strength Index (RSI)56.44
Average Volume (3m)2.75M
Important Dates
VYNE Therapeutics upcoming earnings date is Feb 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date―
Financial Position
VYNE Therapeutics as a current ratio of 4.35, with Debt / Equity ratio of 0.00%
Current Ratio4.35
Quick Ratio4.35
Debt to Market Cap0.00
Net Debt to EBITDA0.45
Interest Coverage Ratio0.00
Taxes
In the past 12 months, VYNE Therapeutics has paid 4.00K in taxes.
Income Tax4.00K
Effective Tax Rate>-0.01
Enterprise Valuation
VYNE Therapeutics EV to EBITDA ratio is -2.82, with an EV/FCF ratio of -3.60.
EV to Sales245.20
EV to EBITDA-2.82
EV to Free Cash Flow-3.60
EV to Operating Cash Flow-3.62
Balance Sheet
VYNE Therapeutics has $32.70M in cash and marketable securities with $0.00 in debt, giving a net cash position of $32.70M billion.
Cash & Marketable Securities$32.70M
Total Debt$0.00
Net Cash$32.70M
Net Cash Per Share$1.28
Tangible Book Value Per Share$1.22
Margins
Gross margin is 16.03%, with operating margin of -8709.98%, and net profit margin of -7950.90%.
Gross Margin16.03%
Operating Margin-8709.98%
Pretax Margin-7944.71%
Net Profit Margin-7950.90%
EBITDA Margin-8709.18%
EBIT Margin-8709.98%
Analyst Forecast
The average price target for VYNE Therapeutics is $2.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.00
Price Target Upside426.32% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast6.29%
EPS Growth Forecast7.42%